Implementation of Cardiovascular Risk management for patients with Rheumatoïd Arthritis (I-CaRe)

Recruiting

• Conditions: 10003216; 10003816; cardiovascular disease and atherosclerosis; 10011082

• Registration Number: NL-OMON41344
• Lead Sponsor: Jan van Breemen Instituut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 3200

Inclusion Criteria

patients who have the diagnosis rheumatoid arthritis according to the ACR classification criteria

Exclusion Criteria

no signed informed consent

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The percentage of RA patients at baseline, 1, 2, 3, 4 and 5 years,<br /><br>participating in this implementation study and their assessed risk profile<br /><br>The calulated difference between 10-years cardiovascular mortality risk at<br /><br>baseline, 1, 2, 3, 4 and 5 years.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>First we will assess the cardiovascular risk profile of all participating RA<br /><br>patients. Then we will calculate the percentages of patients with untreated<br /><br>hypertension, hypercholesterolemia and/or diabetes mellitus type 2 separately.<br /><br><br /><br>The incidence of cardiovascular events, like angina pectoris, myocardial<br /><br>infarction, ischemic heart disease, heart failure, PCI, CABG, CVA, TIA,<br /><br>carotid-endarteriectomy, signs of periferal atherosclerosis. We will compare<br /><br>these incidence rates with the incidence rates of the CARRE study.<br /><br><br /><br>The effect of antihypertenive medication and statins in RA patients after 1,<br /><br>2, 3, 4 and 5 years of CV-RM.<br /><br><br /><br>Compliance of lifestyle advices and prescribed medication<br /><br><br /><br>Patients satisfaction with offered care, assessed with a questionnaire</p><br>